Value of Ki67 in breast cancer: the debate is still open.

摘要

We read with interest the exhaustive review by Yerushalmi and colleagues1 on the potential prognostic and predictive role of Ki67 expression in breast cancer. The authors conclude that, at present, Ki67 cannot be used as a tool for selecting specific chemotherapy or endocrine treatment, nor for assigning patients to specific risk groups. They recommend the adoption of standard methods and cutoff points in interpreting immunohistochemical specimens. Similar conclusions were drawn in other reviews, with the reported cutoffs for Ki67 ranging from 3-5 to 34%.